Expression of CCL5/rantes by Hodgkin and reed-sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue

被引:92
作者
Fischer, M
Juremalm, M
Olsson, N
Backlin, C
Sundström, C
Nilsson, K
Enblad, G
Nilsson, G [1 ]
机构
[1] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, S-75185 Uppsala, Sweden
[2] Uppsala Univ, Dept Oncol Radiol & Clin Immunol, S-75185 Uppsala, Sweden
关键词
CCL5; mast cell; Hodgkin lymphoma;
D O I
10.1002/ijc.11370
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
HL is a malignant lymphoma characterized by a small number of malignant HRS cells among a major population of infiltrating reactive cells, e.g., lymphocytes and eosinophils. We previously reported that mast cells are present in HL-affected lymph nodes and therein are the predominant CD30L-expressing cells. The CD30L expressed on mast cells is functionally active and can provide stimulatory signals to HRS cells. Thus, mast cells constitute an important portion of the infiltrating reactive cells that contribute to tumor progression in HL. Control of the recruitment of this previously unrecognized cell and its interactions with tumor cells are essentially unknown. To elucidate if mast cells might be specifically attracted to the tumor area by chemokines produced by HRS cells, we investigated chemokine expression in HL cell lines and in vivo. By RNase protection assay, mRNA expression of several chemokines could be detected in the cell lines. Despite the heterogeneous expression profile exhibited by the cell lines, 4 of 5 expressed CCL5 (RANTES) mRNA. RT-PCR and immunohistochemistry confirmed expression of CCL5 in vivo. Furthermore, secreted CCL5 was detected in conditioned media from 3 of the cell lines. In a migration assay, we found that CCL5 present in conditioned medium could induce mast cell migration. Taken together, our results suggest that CCL5 produced by HRS cells is one mechanism by which mast cells can be attracted into the tumor tissue in HL. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:197 / 201
页数:5
相关论文
共 33 条
  • [1] CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease
    Buri, C
    Körner, M
    Schärli, P
    Cefai, D
    Uguccioni, M
    Mueller, C
    Laissue, JA
    Mazzucchelli, L
    [J]. BLOOD, 2001, 97 (06) : 1543 - 1548
  • [2] Inflammatory cells and cancer: Think different!
    Coussens, LM
    Werb, Z
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (06) : F23 - F26
  • [3] A QUANTITATIVE STUDY OF MAST-CELLS IN HODGKINS-DISEASE
    CROCKER, J
    SMITH, PJ
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1984, 37 (05) : 519 - 522
  • [4] DEY P, 1995, ANAL QUANT CYTOL, V17, P219
  • [5] HODGKINS-DISEASE - ESTABLISHMENT AND CHARACTERIZATION OF 4 INVITRO-CELL LINES
    DIEHL, V
    KIRCHNER, HH
    SCHAADT, M
    FONATSCH, C
    STEIN, H
    GERDES, J
    BOIE, C
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1981, 101 (01) : 111 - 124
  • [6] Dimitriadou V, 1997, ANTICANCER RES, V17, P1541
  • [7] HODGKINS-DISEASE DERIVED CELL-LINES HDLM-2 AND L-428 - COMPARISON OF MORPHOLOGY, IMMUNOLOGICAL AND ISOENZYME PROFILES
    DREXLER, HG
    GAEDICKE, G
    LOK, MS
    DIEHL, V
    MINOWADA, J
    [J]. LEUKEMIA RESEARCH, 1986, 10 (05) : 487 - 500
  • [8] Mast cells and basophils
    Galli, SJ
    [J]. CURRENT OPINION IN HEMATOLOGY, 2000, 7 (01) : 32 - 39
  • [9] Hodgkin's disease: A tumor with disturbed immunological pathways
    Gruss, HJ
    Pinto, A
    Duyster, J
    Poppema, S
    Herrmann, F
    [J]. IMMUNOLOGY TODAY, 1997, 18 (04): : 156 - 163
  • [10] The hallmarks of cancer
    Hanahan, D
    Weinberg, RA
    [J]. CELL, 2000, 100 (01) : 57 - 70